Scarica l'app Stockscreener
0.8524
4.54%
-0.0405
Tenaya Therapeutics Inc Borsa (TNYA) Ultime notizie
How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story - simplywall.st
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026 - Meyka
Tenaya Therapeutics (TNYA) Valuation After TN-301 Data And New Alnylam Collaboration - simplywall.st
William Blair reiterates Outperform on Tenaya Therapeutics stock By Investing.com - Investing.com Canada
William Blair reiterates Outperform on Tenaya Therapeutics stock - Investing.com
Leerink Partners reiterates Outperform on Tenaya stock at $2 - Investing.com
Tenaya Therapeutics Reports Promising 2025 Results, Advances Gene Therapy Programs, and Extends Cash Runway Into 2027 - Minichart
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal - Yahoo Finance
Tenaya Therapeutics: Advancing Genetic Medicines and Small Molecule Therapies for Heart Disease Treatment - Minichart
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027 - TradingView
Tenaya Therapeutics (NASDAQ:TNYA) Issues Earnings Results, Meets Expectations - MarketBeat
TNYA: Clinical progress, Alnylam deal, and financing extend cash runway into 2027 - TradingView
Tenaya Therapeutics (NASDAQ: TNYA) narrows 2025 loss and extends cash runway to 2027 - Stock Titan
Q4 and 2025 results drive business momentum, Tenaya Therapeutics outlines - Traders Union
Heart gene therapy data and $1.1B Alnylam deal help Tenaya fund work to 2027 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
TNYA pulls back after hours following significant $1.13B deal-spurred rally - MSN
Tenaya Therapeutics Soars with Major Collaboration Deal - timothysykes.com
Tenaya Therapeutics Reports TN-301 Outperforms Givinostat in Enhancing Muscle Function and Addressing DMD Cardiomyopathy - Quiver Quantitative
Experimental drug TN-301 restores muscle strength in Duchenne mice - Stock Titan
Leerink Partners Global Biopharma Conference 2026: TEVA, CYTK, IMRX, TNYA And More Set To Present - RTTNews
Morgan Stanley reduces PT on Tenaya Therapeutics (TNYA), keeps constructive stance on US small- to mid-cap biotech - MSN
Tenaya Therapeutics, Inc.Common Stock (NQ: TNYA - The Chronicle-Journal
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Partnership With Tenaya Therapeutics - simplywall.st
Tenaya Therapeutics announces orderly board leadership transition - MSN
Lifesci Capital Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Strong-Buy - MarketBeat
Hedge Fund Bets: Can Tenaya Therapeutics Inc lead its sector in growth2025 Market Sentiment & Precise Swing Trade Alerts - baoquankhu1.vn
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - bioworld.com
Tenaya Therapeutics inks $1 billion-plus research deal with Alnylam - The Pharmaletter
Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Sahm
TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally - Asianet Newsable
Tenaya To Evaluate Genetic Cardiovascular Targets For Alnylam - Citeline News & Insights
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments - marketscreener.com
Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam - marketscreener.com
Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration - TipRanks
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - Seeking Alpha
Tenaya Therapeutics enters into research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics - marketscreener.com
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics - The Manila Times
Biotech duo chases new heart disease genes in $1.13B research pact - Stock Titan
TNYA SEC FilingsTenaya Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
TNYA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Update Report: Is Tenaya Therapeutics Inc in a long term uptrendJuly 2025 Closing Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026 - Bitget
Biotech Tenaya Therapeutics to stream CEO chat from Miami conference - Stock Titan
Tenaya Therapeutics (TNYA) Projected to Post Earnings on Monday - MarketBeat
Tenaya Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Group Gp Lp Column III Sells 3,511,826 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock - MarketBeat
Insider Selling: Tenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Sells 658,440 Shares of Stock - MarketBeat
Venture firm Column Group (TNYA) details 23.1% Tenaya stake and stock sales - Stock Titan
Column Group funds trim Tenaya (TNYA) stake with 4.17M-share sale - Stock Titan
[144] Tenaya Therapeutics, Inc. SEC Filing - Stock Titan
Column Group files Form 144 for Tenaya Therapeutics (NASDAQ: TNYA) with share sale rows - Stock Titan
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):